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cu.2012.Abstract The objective of this study was formulation, development and evaluation of meloxicam
orodispersible tablets. ODTs were prepared by two methods including sublimation technique where
different subliming agents like camphor, menthol and thymol were used with Ac-Di-Sol as a super-
disintegrant. Each subliming agent was used in three different concentrations (5, 10 and 15% w/w).
Tablets were ﬁrst prepared and later exposed to vacuum. Meloxicam ODTs were also prepared by
freeze-drying an aqueous dispersion of meloxicam containing a matrix former, a sugar alcohol, and
a collapse protectant. In addition, different disintegration accelerators were tested (each in 1% w/v)
including PVP K25, PVP K90, PEG 6000, PEG 4000, PEG 400, tween 80 and tween 20. The pre-
pared ODTs from two methods were evaluated for weight variation, thickness, drug content, fria-
bility, hardness, wetting time, in vitro disintegration time and in vitro dissolution study. The best
formulation was subjected to stability testing for 3 months at temperatures 40 C and 75% relative
humidity and at 60 C. All formulations showed disintegration time ranging from 1 to 46 s. All the
prepared formulae complied with the pharmacopoeial requirements of the drug contents. T17 gave
the best in vitro disintegration and dissolution results. ODT formula T17 has shown no appreciable
changes with respect to physical characters, meloxicam content and dissolution proﬁles when stored
at elevated temperatures. In conclusion the results of this work suggest that orodispersible tablets of
meloxicam with rapid disintegration time, fast drug release and good hardness can be efﬁciently and
successfully formulated by employing freeze drying and sublimation methods.
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ODTs are solid dosage forms rapidly disintegrate in few sec-
onds, when placed on the tongue. Orally disintegrating tablets
have better patient acceptance and compliance and may offer
improved biopharmaceutical properties, efﬁcacy and increased
bioavailability compared with conventional oral dosage
forms.1hosting by Elsevier B.V.Open access under CC BY-NC-ND license.
Table 1 Composition of meloxicam ODTs prepared by sublimation method.
Ingredients (mg) Formula
T1 T2 T3 T4 T5 T6 T7 T8 T9
Meloxicam 7.5 7.5 7.5 7.5 7.5 7.5 7.5 7.5 7.5
Camphor 6 12 18 – – – – – –
Menthol – – – 6 12 18 – – –
Thymol – – – – – – 6 12 18
Ac-Di-Sol 12 12 12 12 12 12 12 12 12
Saccharin sodium 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2
Magnesium stearate 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6
Mannitol up to 120 120 120 120 120 120 120 120 120
90 A.A. Elbary et al.Prescription ODT products initially were developed to
overcome the difﬁculty in swallowing among pediatric and
geriatric populations who have difﬁculty in swallowing con-
ventional tablets and capsules.
Today, ODTs are more widely available as OTC products
for the management of many conditions such as allergies, cold,
and ﬂu symptoms.2 The presence of a highly porous surface in
the tablet matrix is the key factor for rapid disintegration of
ODT.3
To improve the porosity, volatile substances such as sub-
liming agents can be used in tableting process4–6, which subli-
mated from the formed tablet. Also freeze-drying technique is
used to form a highly porous ODT.7,8
Meloxicam is an oxicam derivative belongs to a non steroi-
dal anti inﬂammatory group developed for the treatment of
many inﬂammatory diseases such as rheumatoid arthritis and
osteoarthritis. It is reported to be a selective inhibitor of cyclo
oxygenase 2 (COX-2).9
Meloxicam is practically insoluble in water (12 lg/ml), its
poor solubility and wettability lead to poor dissolution and
hence, variation in bioavailability.10 Several approaches have
been carried out to increase the aqueous solubility of meloxi-
cam using solid dispersion,11–15 complexation with cyclodex-
trins16–21 and nanoparticles formation.22
In this study, ODTs containing meloxicam were prepared in
order to improve its dissolution rate and hence its oral
bioavailability.
2. Materials and methods
2.1. Materials
Meloxicam was obtained as a gift sample from Amoun phar-
maceutical company (Egypt), Crosscarmellose sodiumTable 2 Composition of meloxicam ODTs prepared by freeze dryi
Formula Gelatin (% w/v) Mannitol (% w/v) Glycine (% w
T10 0.25 8.86 0.886
T11 0.50 8.86 0.886
T12 1.00 8.86 0.886
T13 0.50 8.86 0.886
T14 0.50 8.86 0.886
T15 0.50 8.86 0.886
T16 0.50 8.86 0.886
T17 0.50 8.86 0.886
T18 0.50 8.86 0.886
T19 0.50 8.86 0.886(Ac-Di-Sol) was obtained as a gift sample from DMV-Fonter-
ra Excipients (Germany), camphor, menthol, polyethylene gly-
col (grades 400, 4000 and 6000), tween 80, tween 20 and
thymol were purchased from Sigma–Aldrich (USA), mannitol,
magnesium stearate, gelatin and glycine were supplied from
(ADWIC, EGYPT). Polyvinyl pyrrolidone K25 and K90 were
purchased from (Fluka, Switzerland). Sodium saccharin was
kindly supplied by El Nile Company (Egypt). All other ingre-
dients and solvents used were of analytical grade.
2.2. Methods
2.2.1. Characterization of drug and excipients
2.2.1.1. Differential scanning calorimetry (DSC). Samples of
5 mg pure meloxicam and its physical mixtures with different
excipients were hermetically sealed in ﬂat bottomed aluminium
pans and heated in the DSC instrument (Shimadzu, Japan) in
an atmosphere of nitrogen to eliminate the oxidative and pyro-
lytic effects. The heating rate was 5 C/min in a temperature
range of 25–300 C. The DSC thermograms were recorded.
2.2.1.2. Fourier-transform infra red spectroscopy (FTIR). The
IR spectra of the pure drug and drug excipient mixtures were
recorded on FTIR spectrophotometer (Shimadzu IR-345, Ja-
pan). Samples of 2–3 mg were mixed with about 400 mg of
dry potassium bromide then compressed into transparent disks
under pressure of 10.000–15.000 psi. The IR spectra were re-
corded at scanning range from 500–4000 cm1 and resolution
of 4 cm1.
2.2.1.3. Preparation of meloxicam ODTs by sublimation
method. As shown in Table 1, different ODTs of meloxicam
namely T1–T9 were prepared using different subliming agents
such as camphor, thymol and menthol in concentrations ofng method.
/v) Disintegration accelerators (% w/v) Meloxicam (% w/v)
– 0.75
– 0.75
– 0.75
1% PVP K90 0.75
1% PVP K25 0.75
1% PEG 6000 0.75
1% PEG 4000 0.75
1% PEG 400 0.75
1% Tween 80 0.75
1% Tween 20 0.75
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weight.
All of the materials were passed through sieve No. 60 be-
fore use and the accurately weighed amounts of ingredients
were thoroughly mixed and compressed into 120 mg tablets
using single punch machine (Shanghai Tianhe, China) of
8 mm ﬂat punch and die set. Meloxicam tablets were then
placed in an oven at 40 C till a constant weight is obtained.
2.2.1.4. Preparation of meloxicam ODTs by freeze drying
method. Meloxicam ODTs T10–T19 were prepared using gela-
tin as a matrix former, a sugar alcohol (mannitol) and a col-
lapse protectant (glycine). Gelatin was used in three different
concentrations 0.25%, 0.5% and 1% w/v, respectively while
glycine was used at a concentration of 0.886% w/v.8
An accurately weighed amount of meloxicam, mannitol and
glycine was mixed then added to hot gelatin solution, then dis-
persed using a magnetic stirrer to result in a dose of 7.5 mg
meloxicam per 1 ml. One milliliter of the suspension was then
poured in each pocket of a PVC blister pack with a diameter of
18 mm and a depth of 5 mm resulting in a dose of 7.5 mg per
tablet. The frozen tablets (at 22 C) were placed in a lyoph-
ilizer for 24 h using a freeze dryer (Novalyphe-NL 500, Hol-
brook, USA).
Based on tablet properties, the best formula was taken for-
ward to the next step which involved the addition of a water
soluble surface active agent or polymer in order to improve
disintegration time and/or friability.
The disintegration accelerators were: three grades of PEG
namely PEG 400, PEG 4000 and PEG 6000; two grades of
PVP namely PVP K25 and PVP K90 and two grades of tween
namely tween 20 and tween 80.
All of these were added at a concentration of 1% w/v. The
detailed composition of the prepared ODTs is presented in Ta-
ble 2. The prepared ODTs were kept in desiccators over cal-
cium chloride at room temperature.
2.3. Characterization of the prepared orodispersible tablets
2.3.1. Uniformity of weight
Ten tablets from each formula were individually weighed and
the mean weight was calculated.
2.3.2. Uniformity of ODTs thickness and diameter
The diameter and thickness of 10 tablets were measured using a
digital Valiner caliber (China) at three different positions. Re-
sults were reported as the mean (±SD) of three measurements.
2.3.3. Friability test
Ten pre-weighed tablets from each formula were tested, accu-
rately placed in the drum of the friabilator (Pharma Test, Ger-
many) and rotated at 25 rpm for a period of 4 min, then
reweighed. The percentage loss in weights was calculated and
taken as a measure of friability.23
2.3.4. Hardness
The average breaking strength of tablets was determined by tab-
let hardness tester (Dr. Schlenger pharmaton, USA).23 From
each formula, 10 tablets were tested for their hardness; themean
hardness (±SD) in kg of each formula was determined.2.3.5. Content uniformity
Ten tablets were used in this test, where each one was crushed
and transferred into a 100 ml volumetric ﬂask. The ﬂasks were
brought to volume by phosphate buffer pH 6.8. The ﬂasks
were placed onto a sonicator till complete dissolution; 1 ml
of the solution was ﬁltered through a Millipore ﬁlter of
0.45 lm pore size then introduced into a 25 ml volumetric ﬂask
which was completed to volume by phosphate buffer.
The absorbance of the solution was measured using a UV
spectrophotometer (Jasko V-530, Japan) against the blank
phosphate buffer (pH 6.8) at 359 nm. The tablets meet the test
if the mean drug content lies within the range of 85–115% of
the labeled potency.24
2.3.6. In vitro disintegration time
The test is carried out on six tablets using the apparatus (Han-
son research, USA). 900 ml phosphate buffer (pH 6.8) at
37 ± 0.5 C was used as a disintegration medium and the time
taken for complete disintegration of the tablet with no palpable
mass remaining in the apparatus was measured in seconds.25
2.3.7. In vitro dissolution studies
The dissolution proﬁles of meloxicam from ODTs were deter-
mined in a dissolution tester, apparatus II (Hanson Research,
SR 8 Plus model, USA). All tests were conducted in 900 ml
phosphate buffer (pH = 6.8) at a temperature of
37 ± 0.5 C with a paddle rotation speed at 50 rpm.
At speciﬁed time intervals 1, 3, 5, 7, 10, 15, 20, 25 and
30 min; 5 ml of dissolution medium was withdrawn and re-
placed with an equal volume of medium to maintain a constant
total volume. Samples were ﬁltered through a 0.45 lm Milli-
pore ﬁlter and assayed for drug content spectrophotometri-
cally at 359 nm.
The drug dissolution from commercial product Mobic7.5
was carried out using the same dissolution apparatus under the
same conditions. All experiments were done in triplicate.
Dissolution proﬁles were evaluated by calculating the disso-
lution efﬁciency parameter at 10 min (DE10min), from the area
under the dissolution curve, according to the method of
Khan.26 Additionally, the initial dissolution rate (IDR, % dis-
solved/min) was computed over the ﬁrst 5 min of dissolution.
2.3.8. Wetting time
Ten milliliters of water soluble dye eosin solution is added to
petri dish containing ﬁve circular ﬁlter papers of 10 cm diam-
eter. Tablets were carefully placed on the surface of the ﬁlter
paper and the time required for water to reach upper surface
of the tablet was noted as the wetting time.27 The test results
were presented as mean value of three determinations (± SD).
2.3.9. Moisture uptake studies
Ten tablets from each formulation were kept in a desiccator
over calcium chloride at 37 C for 24 h. Then the tablets were
weighed and exposed to 75% relative humidity (using satu-
rated sodium chloride solution) at room temperature for
2 weeks. One tablet without superdisintegrant as control was
kept to assess the moisture uptake due to other excipients.
Tablets were weighed and the percentage increase in weight
was recorded.3 The results were presented as mean value of
three determinations (± SD).
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2.4.1. Accelerated Stability Testing
Accelerated stability studies on meloxicam ODT formula T17
were carried out by storing the tablets in PVC blisters covered
with aluminum foil and stored at 40 and 60 C at 75% relative
humidity in ovens for a period of 12 weeks. Samples were with-
drawn periodically at 1, 2, 4, 6, 8, and 12 weeks and examined
for any physical changes as well as for their drug content using
HPLC stability indicating method.28
2.4.1.1. Chromatographic conditions. The mobile phase was a
mixture of acetonitrile:water:glacial acetic acid in a ratio of
45%:50%:5% (v/v/v). The mobile phase was delivered into
the HPLC apparatus consisting of: Pump L-7110 (Hitachi
Ltd., Japan), UV/VIS detector (SPD-10A), Integrator C-
R6A chromatopac (Hitachi Ltd, Japan), and C18 Column
0.46 I.D · 25 cm (packed with Nucleosil 120 5l, Teknokroma.
Spain) at a ﬂow rate of 1 ml/min, the detection was conducted
at 355 nm. In vitro standard calibration curve was made over a
concentration range from 4 to 20 lg/ml using tenoxicam as an
internal standard.
2.4.1.2. Quantitation. During the period of storage, samples of
six tablets were withdrawn at speciﬁed times and analyzed
chemically as follows: the dosage form was crushed and dis-
solved in 100 ml mobile phase, the solution was ﬁltered and
the ﬁrst 20 ml was rejected. One milliliter aliquot of the pre-
pared solution was transferred to a 10 ml volumetric ﬂask,
1 ml internal standard solution (100 lg/ml) was added and
the volume was completed with the mobile phase. The samples
were ﬁltered through a 0.45 lm Millipore ﬁlter and degassed.
Twenty microliters of the above solution was injected into
the column for quantitation. The unknown concentration of
meloxicam in each dosage unit was calculated.
2.4.1.3. Kinetic analysis of chemical stability data. The stability
data were analyzed according to zero and ﬁrst order. The ki-
netic parameters namely, the decomposition rate constant
(K) and t50% were then computed according to the determined
order at each of the two temperatures.
The K values at different temperatures were plotted against
the reciprocal of the corresponding absolute temperatures on
the logarithmic scale according to the Arrhenius plot for the
determination of the predictive shelf life at room temperature.29
2.4.2. Effect of humid storage on the release of meloxicam from
stored ODTs
In order to study the effect of storage at high temperature and
humidity on the release of meloxicam from the selected for-
mula, dissolution study has been conducted on the samples ta-
ken from the stored formula at 40 C and 75% relative
humidity after 4, 8 and 12 weeks as described earlier.Figure 1 DSC thermogram of (A) pure meloxicam, (B)
meloxicam + Ac-Di-Sol, (C) meloxicam + mannitol, (D) meloxi-
cam + saccharin sodium, (E) meloxicam + magnesium stearate,
(F) meloxicam + camphor, (G) meloxicam +menthol, (H)
meloxicam + thymol, (I) meloxicam + PVP K90, (J) meloxi-
cam + PVP K25, (K) meloxicam + PEG 6000 and (L) meloxi-
cam + PEG 4000.3. Results and discussion
3.1. Characterization of drug and excipients
The DSC thermogram of pure meloxicam (Fig. 1) showed one
main characteristic sharp melting endothermic peak at255.8 C. The DSC thermograms of physical mixtures of drug
and different excipients revealed no signiﬁcant change in the
melting point of meloxicam in the presence of excipients, indi-
cating no interaction between the drug and excipients.
IR spectra of meloxicam and its physical mixtures with for-
mulation excipients were determined using FTIR and are pre-
sented in Fig. 2. Pure meloxicam spectrum showed sharp
characteristic peaks at 3285 cm1(–NH) stretching, at
1618 cm1 for (C‚O) stretching of the amide, at 1452 cm1
for (C‚C) stretching of the aromatic ring, at 1345 and 1159
for two sulphonyl groups (S‚O stretching vibration). FTIR
spectra of meloxicam and its physical mixture with excipients
showed the same characteristic bands of the drug in the same
regions and at the same ranges, indicating that there was no
interaction between the drug and excipients used.
3.2. Characterization of meloxicam ODTs
Water insoluble diluents such as microcrystalline cellulose,
low-substituted hydroxyl propyl cellulose and dicalcium phos-
phate were omitted from the study as they are expected to
make patients feel grittiness in their mouth due to the incom-
plete solubilization of this type of excipients in saliva.
Tablet formulae T1–T9 were prepared by sublimation
method. Mannitol was selected as a diluent considering the
advantages of good aqueous solubility, easy availability and
negative heat of dissolution.
Table 3 shows that all the formulated ODTs exhibited low
weight variation range from 119.6 to 120.8 mg with standard
Figure 2 FTIR spectra of (A) pure meloxicam, (B) meloxicam + Ac-Di-Sol, (C) meloxicam + mannitol, (D) meloxicam + saccharin
sodium, (E) meloxicam + magnesium stearate; (F) meloxicam + camphor, (G) meloxicam + menthol, (H) meloxicam + thymol, (I)
meloxicam + PVP K90, (J) meloxicam + PVP K25, (K) meloxicam + PEG 6000 and (L) meloxicam + PEG 4000.
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in the range of 0.73–0.82 cm while the values of the tablet
thickness were in the range of 0.2–0.23 cm. The drug content
of the prepared formulations was found to be between
95.1% and 98.6% which was found to conform to pharmaco-
poeial limits.
Each subliming agent was used in three concentrations 5%,
10%, and 15% w/w to study their effects on disintegration
time. Formulae T1–T3 were prepared containing camphor,
formulae T4–T6 containing menthol while formulae T7–T9
containing thymol. Addition of subliming agents had no pro-
nounced effect on hardness and friability of the prepared tab-
lets. The disintegration time is decreased with increasing the
subliming agent concentration. The subliming agents could
be arranged in a descending order of decreasing disintegration
time as follows: camphor > menthol > thymol.
Formula T3 containing camphor 15% w/w exhibited the
shortest disintegration time about 9 s. The porous structure
is responsible for faster water uptake, so it facilitates the action
of Ac-Di-Sol in bringing about faster disintegration.
All tablet formulations showed rapid wetting time ranging
from 10.1 to 45.4 s. These results correlate well with disintegra-
tion results. All tablet formulations showed good stability
when exposed to 75% relative humidity and ﬁnal % increase
in weight ranged from 1.1% to 3.9%.As shown in Table 4 formulae T10–T19 were prepared by
freeze drying method. The values of the tablet diameter were
in the range of 1.6–1.7 cm while the values of the tablet thick-
ness were in the range of 0.4–0.43 cm. The mean% meloxicam
content in ODTs was found to be more than 96% from all
formulations.
Formula T10 containing 0.25% gelatin was friable and
showed percentage weight loss that exceeded the pharmaco-
poeial limits. Friability testing showed that ODTs formulated
with 0.5% and 1% gelatin showed no cracked or broken tab-
lets after tumbling and the calculated percentage weight loss
was found to be within the acceptable range (less than 1%)
indicating that the tablets were non fragile and could be easily
handled.
Although formula T12, containing 1% gelatin was elegant
tablet, it exhibited disintegration time of 110.2 s. It has been re-
ported that high gelatin concentration usually results in a rigid
three dimensional network after freeze drying due to the pres-
ence of high number of gelatin ﬁbers forming cross links and
inter chain H-bonds, thereby leading to increased overall hard-
ness of the tablets.30 Formulae T10 and T12 were excluded
from the study. Formula T11 exhibited disintegration time of
67.1 s. So that the addition of disintegration accelerator was
a necessary matter to enhance the disintegration and dissolu-
tion of the tablets.
Table 3 Evaluation of ODTs of meloxicam prepared by sublimation method.
Formula Mean weight
(mg) ± S.D
Mean diameter
(cm) ± S.D
Mean thickness
(cm) ± S.D
% Drug
content ± S.D
%
Friability
Hardness
(kg) ± S.D
Disintegration
time
(sec) ± S.D
Wetting time
(sec) ± S.D
% Increase
in weight
(after 2 weeks)
T1 120.2 ± 0.98 0.73 ± 0.014 0.20 ± 0.028 97.9 ± 0.45 0.42 3.0 ± 0.77 33 ± 0.68 16.9 ± 0.27 1.1
T2 120.4 ± 0.96 0.82 ± 0.003 0.21 ± 0.017 99.9 ± 0.59 0.86 2.9 ± 1.83 15 ± 0.89 12.4 ± 0.49 1.6
T3 120.5 ± 0.54 0.75 ± 0.005 0.22 ± 0.019 100.3 ± 1.36 0.25 3.7 ± 0.71 9 ± 1.02 10.1 ± 0.60 1.9
T4 120.4 ± 0.58 0.81 ± 0.006 0.23 ± 0.020 97.3 ± 1.74 0.46 3.2 ± 1.50 14 ± 1.07 21.1 ± 0.70 1.3
T5 120.3 ± 0.89 0.81 ± 0.016 0.20 ± 0.030 97.1 ± 0.58 0.70 3.0 ± 0.78 13 ± 0.64 20.1 ± 0.88 2.1
T6 119.8 ± 0.44 0.80 ± 0.009 0.20 ± 0.023 98.6 ± 0.69 0.63 3.3 ± 1.71 12 ± 0.88 14.1 ± 0.18 2.2
T7 120.8 ± 0.47 0.80 ± 0.018 0.21 ± 0.031 96.8 ± 1.69 0.53 3.1 ± 1.44 46 ± 1.03 45.4 ± 0.31 3.7
T8 119.6 ± 0.36 0.81 ± 0.013 0.21 ± 0.021 98.0 ± 0.70 0.41 3.0 ± 0.53 17 ± 0.51 44.4 ± 0.51 3.9
T9 120.5 ± 0.31 0.80 ± 0.007 0.21 ± 0.026 95.1 ± 1.18 0.90 2.7 ± 1.85 12 ± 0.11 10.9 ± 0.10 3.6
Table 4 Evaluation of ODTs of meloxicam prepared by freeze drying method.
Formula Mean weight
(mg) ± S.D
Mean diameter
(cm) ± S.D
Mean thickness
(cm) ± S.D
%
Drug content ± S.D
%
Friability
Disintegration
time (sec) ± S.D
Wetting time
(sec) ± S.D
% Increase in
weight (after 2 weeks)
T13 119.5 ± 0.84 1.60 ± 0.004 0.40 ± 0.039 101.3 ± 0.63 0.77 5 ± 0.25 4.5 ± 0.76 2.1
T14 119.2 ± 1.13 1.63 ± 0.006 0.41 ± 0.023 100.1 ± 0.58 0.83 4 ± 0.12 3.1 ± 0.53 2.0
T15 119.2 ± 1.03 1.66 ± 0.007 0.41 ± 0.031 102.2 ± 0.77 0.78 3 ± 0.24 2.5 ± 0.42 2.6
T16 119.6 ± 0.88 1.61 ± 0.018 0.43 ± 0.021 101.5 ± 0.84 0.84 3 ± 0.54 3.4 ± 0.74 2.0
T17 118.9 ± 0.58 1.66 ± 0.019 0.40 ± 0.017 102.0 ± 1.50 0.93 1 ± 0.35 2.5 ± 0.59 1.9
T18 119.0 ± 1.22 1.68 ± 0.014 0.43 ± 0.003 96.9 ± 2.25 0.95 5 ± 0.65 6.6 ± 0.81 2.2
T19 119.1 ± 1.39 1.70 ± 0.085 0.42 ± 0.064 98.5 ± 0.95 0.97 3 ± 0.52 5.4 ± 0.44 1.7
Figure 3 Dissolution proﬁles of meloxicam from its ODT
formulae T1–T9 prepared by sublimation method.
94 A.A. Elbary et al.Formula T17 containing 1% PEG 400 as a disintegration
accelerator, exhibited the shortest disintegration time of about
1 s. Short disintegration time of these formulations is indica-
tive of the highly porous nature of the tablet matrix. All ODTs
showed good stability when exposed to 75% relative humidity
and ﬁnal % increase in weight ranged from 1.7% to 2.6%.
3.3. In vitro dissolution studies
The dissolution proﬁle of meloxicam formulae T1–T9 com-
pared to the market product Mobic7.5 is graphically illus-
trated in Fig. 3. Remarkable differences in the dissolution
proﬁles of the prepared ODTs and those of Mobic 7.5 are
observed. The extent of dissolution of meloxicam from the
marketed product Mobic7.5 was 77.02% in 30 min. All for-
mulae showed acceptable dissolution rate, where more than
85% of the labeled dose is dissolved at 30 min. These results
indicate that sublimation process used to prepare the ODTs
enhanced the extent and rate of dissolution of meloxicam.
Formula T3 containing camphor 15% w/w showed the
highest dissolution rate where 94.3% of the labeled dose is dis-
solved at 10 min; this may be due to faster uptake of water ow-
ing to the porous structure formed thus facilitating the
disintegrant to bring about faster disintegration and also
improving dissolution. This was in accordance with results ob-
tained by Furtado et al.31 they studied the effect of camphor as
a subliming agent on the mouth dissolving property of famoti-
dine tablets.
The dissolution proﬁles of ODT formulae T13–T19 are
graphically illustrated in Fig. 4. The percentage of drug dis-
solved from all ODT formulations was almost 100% after
20 min except formulae (T18 and T19). It indicates the
effectiveness of the freeze drying method in enhancing thedissolution of meloxicam. It could be attributed to the forma-
tion of porous structure in lyophilized tablets in addition to
incorporation of water soluble excipients.
The percentage of meloxicam dissolved from ODTs con-
taining PEGs was inversely proportional to the chain length
of PEG. This may be attributed to the fact that the water sol-
ubility of PEGs decreases with an increase in the molecular
weight of the polymer. This result is consistent with the results
of previous study that reported on the dissolution properties of
PEGs and PEG drug systems.8
Dissolution results from ODTs containing PVP showed
that the dissolution rate was dependant on the type of PVP
used. In formula T14 the addition of PVP K25, leads to greater
dissolution rate than that of formula T13 containing PVP K90.
Figure 4 Dissolution proﬁles of meloxicam from its ODT
formulae T13–T19 prepared by freeze drying method.
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101.68% of the labeled dose is dissolved at 3 min and the
shortest disintegration time (1 s). The increased dissolution
rate of meloxicam from T17 could be attributed to several fac-
tors such as solubilization of the drug in the hydrophilic poly-
mer, conversion to amorphous state and improved wettability
and dispersibility of meloxicam.32,33 Babu et al. tested the sol-
ubility of meloxicam with different solvents and among the
solvents tested, PEG 400 was the best one where solubility of
meloxicam in PEG 400 was 40 folds higher than in water.34
The percentage of meloxicam dissolved after 30 min from
all prepared meloxicam ODTs was signiﬁcantly greater
(P< 0.05) than that from market product Mobic7.5 tablets.
The dissolution efﬁciency data calculated based on 10 min
(DE10 min) and the initial dissolution rate during the ﬁrst
5 min (IDR) of all the systems are compiled in Table 5.Table 5 Values of IDRb and DE10 min
a of the release proﬁles
of meloxicam ODTs prepared by different methods.
Formula DE10 min (%) ± S.D IDR (% dissolved/min) ± S.D
Mobic 7.5 16.70 ± 1.36 2.65 ± 1.56
T1 76.92 ± 1.25 16.27 ± 1.34
T2 77.02 ± 2.95 16.54 ± 1.22
T3 83.81 ± 3.02 17.50 ± 1.54
T4 37.52 ± 2.06 7.36 ± 1.22
T5 49.78 ± 1.65 10.55 ± 1.56
T6 66.88 ± 2.02 14.50 ± 1.67
T7 40.99 ± 1.26 8.40 ± 1.93
T8 62.15 ± 1.41 13.64 ± 1.41
T9 69.14 ± 1.36 14.07 ± 1.56
T13 84.60 ± 1.25 17.78 ± 1.34
T14 86.09 ± 2.95 18.06 ± 1.22
T15 90.58 ± 3.02 19.40 ± 1.54
T16 94.25 ± 2.06 20.00 ± 1.22
T17 94.92 ± 1.65 20.00 ± 1.56
T18 75.99 ± 2.02 15.87 ± 1.67
T19 81.15 ± 1.26 16.98 ± 1.93
a DE10 min: dissolution efﬁciency.
b IDR: initial dissolution rate.The dissolution proﬁle of meloxicam from Mobic7.5 tab-
lets showed DE10 min value of 16.70% and IDR of 2.65% indi-
cating incomplete dissolution which could be due to less
wettability of the drug.
The DE10 min value of meloxicam from T17 showed the
maximum value of 94.92% and marked increase initial dissolu-
tion rate compared with the other tablet formulae.
3.4. Stability testing
None of the stored tablets at 40 and 60 ± 0.5 C with relative
humidity 75% for a period of 12 weeks showed any changes in
color or appearance throughout the storage period.
Fig. 5 shows a typical chromatogram for meloxicam in the
mobile phase, which was detected at kmax 355 nm. Meloxicam
and tenoxicam were well separated and their retention times
were 8.3 and 4.6 min, respectively. Both peaks were sharp
and symmetrical with good baseline resolution and minimal
tailings, thus facilitating accurate measurements of the peak
area ratios.
Tenoxicam is a good internal standard because of its ade-
quate retention time and similar spectral properties to meloxi-
cam. The calibration curve was highly linear over the
concentration range used with a correlation coefﬁcient
0.9998. The percent remaining of meloxicam for the prepared
formula T17 at 40 and 60 C for 12 weeks was within the per-
mitted limits by the USP (90–110%) up to the end of the stor-
age period.24
Kinetic analysis of the stability data obtained from formula
T17 indicates that the degradation follows ﬁrst-order kinetics.
Fig. 6, illustrates the percentage drug remained in the prepared
ODT at different temperatures according to ﬁrst-order
kinetics.Figure 5 Chromatogram of meloxicam in the mobile phase
acetonitrile:water:glacial acetic acid (45%:50%:5% v/v/v) detected
at kmax 355 nm.
Figure 6 Plot of log % drug remained versus time after storage
of ODT formula T17 for 12 weeks at 40 and 60 C according to
ﬁrst-order kinetics.
Figure 7 Arrhenius plot of logK values of meloxicam ODT
formula T17 after 12 weeks storage at different temperatures.
96 A.A. Elbary et al.The decomposition rate constants (K values) of the tested
formula were plotted graphically on logarithmic scale as illus-
trated in Fig. 7 respectively and the K value at 25 C was ob-
tained. The predictive shelf life was calculated according to
the equation: t90% = 0.105/K25
35, the predictive shelf life for
formula T17 was 3.6 years.
There is no signiﬁcant change in the dissolution proﬁle of
meloxicam from the stored tablets at 40 C and 75% relative
humidity after 4, 8 and 12 weeks (P> 0.05).
4. Conclusion
From the study, it can be concluded that freeze drying and
sublimation methods could be applied effectively in preparing
ODTs with better disintegration and drug release properties.
The prepared ODTs disintegrate within few seconds without
need of water; thereby enhance the absorption leading to in-
creased bioavailability of meloxicam.
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